ESR1 and neoplasm: The IRMA (impact of Recurrence Score on adjuvant treatment decisions and tumor cell dissemination in estrogen receptor-positive and HER2-negative patients with early breast cancer) trial was designed to prospectively evaluate the impact of RS testing on adjuvant therapy recommendations in a clinical real-world setting.